Literature DB >> 20111672

Pulmonary Strongyloidiasis: The Varied Clinical Presentations.

Babak Mokhlesi1, Oksana Shulzhenko, Prasad S Garimella, Leslie Kuma, Catherine Monti.   

Abstract

Strongyloides stercoralis is a unique parasite. It can complete its life cycle entirely within the human host. As a result, an autoinfection cycle is set up. As long as there is an intact immune system, the host can control the parasitic burden, and the organism may persist for years after the initial inoculum. Most infected individuals experience mild gastrointestinal or pulmonary symptoms that may fluctuate for years. When cell-mediated immunity becomes impaired (ie, corticosteroid use, malignancy, acquired immunodeficiency syndrome), the parasite burden will grow, disseminate, and cause hyperinfection. Strongyloidiasis is endemic in the tropical and subtropical areas of the world; additionally, it is also endemic in the southeastern United States. Strongyloidiasis is associated with asthma, preexisting lung disease, and immunosuppression, including acquired immunodeficiency syndrome. Eosinophilia is not a prerequisite; therefore, the diagnosis of strongyloidiasis requires a high index of suspicion.

Entities:  

Year:  2004        PMID: 20111672      PMCID: PMC2812430          DOI: 10.1097/01.cpm.0000107609.50629.69

Source DB:  PubMed          Journal:  Clin Pulm Med


  61 in total

1.  Disseminated lung opacities and cavitation associated with Strongyloides stercoralis and Schistosoma mansoni infection.

Authors:  T Pettersson; R Stenström; H Kyrönseppä
Journal:  Am J Trop Med Hyg       Date:  1974-03       Impact factor: 2.345

2.  Strongyloidiasis of respiratory tract presenting as "asthma".

Authors:  C Nwokolo; E A Imohiosen
Journal:  Br Med J       Date:  1973-04-21

3.  Predictive value of an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of strongyloidiasis.

Authors:  R M Genta
Journal:  Am J Clin Pathol       Date:  1988-03       Impact factor: 2.493

4.  Pulmonary strongyloidiasis: an unusual opportunistic pneumonia in a patient with AIDS.

Authors:  A N Makris; S Sher; C Bertoli; M G Latour
Journal:  AJR Am J Roentgenol       Date:  1993-09       Impact factor: 3.959

5.  Pulmonary strongyloidiasis.

Authors:  P Bruno; K McAllister; J I Matthews
Journal:  South Med J       Date:  1982-03       Impact factor: 0.954

Review 6.  Pulmonary strongyloidiasis: clinical and imaging features.

Authors:  J H Woodring; H Halfhill; J C Reed
Journal:  AJR Am J Roentgenol       Date:  1994-03       Impact factor: 3.959

7.  Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases.

Authors:  A Datry; I Hilmarsdottir; R Mayorga-Sagastume; M Lyagoubi; P Gaxotte; S Biligui; J Chodakewitz; D Neu; M Danis; M Gentilini
Journal:  Trans R Soc Trop Med Hyg       Date:  1994 May-Jun       Impact factor: 2.184

Review 8.  Strongyloidiasis and other intestinal nematode infections.

Authors:  L X Liu; P F Weller
Journal:  Infect Dis Clin North Am       Date:  1993-09       Impact factor: 5.982

Review 9.  Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease.

Authors:  R M Genta
Journal:  Rev Infect Dis       Date:  1989 Sep-Oct

Review 10.  Syndrome of hyperinfection with Strongyloides stercoralis.

Authors:  Y Igra-Siegman; R Kapila; P Sen; Z C Kaminski; D B Louria
Journal:  Rev Infect Dis       Date:  1981 May-Jun
View more
  9 in total

Review 1.  Strongyloides stercoralis hyperinfection syndrome: a deeper understanding of a neglected disease.

Authors:  George Vasquez-Rios; Roberto Pineda-Reyes; Juan Pineda-Reyes; Ricardo Marin; Eloy F Ruiz; Angélica Terashima
Journal:  J Parasit Dis       Date:  2019-02-06

Review 2.  Eosinophilic pneumonias.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

3.  JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.

Authors:  Keiichi Mikasa; Nobuki Aoki; Yosuke Aoki; Shuichi Abe; Satoshi Iwata; Kazunobu Ouchi; Kei Kasahara; Junichi Kadota; Naoki Kishida; Osamu Kobayashi; Hiroshi Sakata; Masahumi Seki; Hiroki Tsukada; Yutaka Tokue; Fukumi Nakamura-Uchiyama; Futoshi Higa; Koichi Maeda; Katsunori Yanagihara; Koichiro Yoshida
Journal:  J Infect Chemother       Date:  2016-06-15       Impact factor: 2.211

4.  Pulmonary Strongyloides stercoralis infection.

Authors:  Canan Dogan; Mine Gayaf; Ayse Ozsoz; Birsen Sahin; Nimet Aksel; Isil Karasu; Zekiye Aydogdu; Nevin Turgay
Journal:  Respir Med Case Rep       Date:  2014-02-03

5.  Pulmonary strongyloidiasis: assessment between manifestation and radiological findings in 16 severe strongyloidiasis cases.

Authors:  Daijiro Nabeya; Shusaku Haranaga; Gretchen Lynn Parrott; Takeshi Kinjo; Saifun Nahar; Teruhisa Tanaka; Tetsuo Hirata; Akira Hokama; Masao Tateyama; Jiro Fujita
Journal:  BMC Infect Dis       Date:  2017-05-02       Impact factor: 3.090

6.  Pulmonary Hyperinfection with Strongyloides stercoralis in an Immunocompetent Patient.

Authors:  Sadik Mohammed; Pradeep Bhatia; Swati Chhabra; Sunit Kumar Gupta; Rakesh Kumar
Journal:  Indian J Crit Care Med       Date:  2019-10

7.  Strongyloides Hyperinfection Syndrome: A Curious Case of Asthma Worsened by Systemic Corticosteroids.

Authors:  Reshad Salam; Ahmed Sharaan; Stephanie M Jackson; Roberto A Solis; Jamshed Zuberi
Journal:  Am J Case Rep       Date:  2020-12-21

Review 8.  Strongyloides stercoralis.

Authors:  Jonathan M Czeresnia; Louis M Weiss
Journal:  Lung       Date:  2022-04-09       Impact factor: 3.777

9.  Rapidly progressive respiratory failure after helminth larvae ingestion.

Authors:  Anahit A Zeynalyan; Balaji Kolasani; Chetan Naik; Christopher J G Sigakis; Leann Silhan; Susan K Mathai
Journal:  BMC Pulm Med       Date:  2021-12-20       Impact factor: 3.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.